TransMedics Group (HAM:8T8) ROCE %: 5.42% (As of Mar. 2026)


HAM:8T8 TransMedics Group Inc HAM:8T8
69 GF Score
Price €60.02
GF Value €162.08
! 9 Warning Signs
View Full Analysis

What is TransMedics Group ROCE %?

TransMedics Group HAM:8T8 -9.99% 69 ROCE % is 5.42% as of Mar. 2026. GuruFocus rates HAM:8T8 with a GF Score™ of 69/100 and a GF Value™ of €162.08. The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TransMedics Group's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.42%.

TransMedics Group  (HAM:8T8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TransMedics Group ROCE % Related Terms

TransMedics Group ROCE % Historical Data

* Premium members only.

The historical data trend for TransMedics Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransMedics Group ROCE % Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.33 -18.11 -3.48 7.33 13.39

TransMedics Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.55 19.02 12.37 10.84 5.42
HAM:8T8
69GF Score
TransMedics Group Inc HAM:8T8
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransMedics Group ROCE % Calculation

TransMedics Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=103.594/( ( (767.893 - 57.217) + (912.391 - 76.266) )/ 2 )
=103.594/( (710.676+836.125)/ 2 )
=103.594/773.4005
=13.39 %

TransMedics Group's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=54.168/( ( (912.391 - 76.266) + (1241.119 - 79.511) )/ 2 )
=54.168/( ( 836.125 + 1161.608 )/ 2 )
=54.168/998.8665
=5.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.42% mean?
TransMedics Group (HAM:8T8) has a ROCE % of 5.42% as of Mar. 2026.
Is TransMedics Group's ROCE % too high?
TransMedics Group's current ROCE % is 5.42%. The Medical Devices & Instruments industry median ROCE % is 2.20. TransMedics Group's value of 5.42% is 146.4% above this industry median. Overall, TransMedics Group has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's ROCE % compare to AXGN and BFLY?
TransMedics Group's ROCE % of 5.42% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. TransMedics Group's value of 5.42% is 146.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current ROCE % of 5.42% is 146.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current ROCE % is 5.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
TransMedics Group (HAM:8T8) has a current ROCE % of 5.42%. The stock's GF Value™ is €162.08, compared to a current price of €60.02 — trading 63% below its estimated fair value. The current ROCE % is 5.42% and 146.4% above the Medical Devices & Instruments industry median of 2.20. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TransMedics Group (HAM:8T8), the current ROCE % is 5.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TransMedics Group (HAM:8T8) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of €60.02 is trading 63% below its estimated GF Value™ of €162.08.

Key valuation signals for HAM:8T8:

  • ROCE %: 5.42%
  • GF Value™: €162.08 vs. price of €60.02 (63% below fair value)
  • GF Score™: 69/100 with 9 warning signs
  • Industry Position: 146.4% above the Medical Devices & Instruments median

No single metric tells the full story. See the HAM:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score

Get the complete analysis for HAM:8T8

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.02
Price
€162.08
GF Value